On a consolidated basis, annual revenue was KRW 7.68 billion in 2022 and KRW 7.77 billion in 2023, which makes 2023 the largest year of the period. Revenue then fell to KRW 6.76 billion in 2024, down 13.0%, and to KRW 5.94 billion in 2025, down 12.1%, which marks two straight years of decline from 2024 through 2025.
The operating result swung from a KRW 210 million profit in 2022 to an operating loss of KRW 1.19 billion in 2023, then widened to KRW 2.23 billion in 2024 and KRW 4.42 billion in 2025. The operating margin moved from 2.7% in 2022 to -15.3% in 2023, -33.0% in 2024, and -74.5% in 2025.
The company attributed the 2025 losses to higher R&D costs tied to the U.S. trial and new clinical programs, lower non-operating income, and derivative valuation losses on convertible bonds.
Net income attributable to controlling shareholders turned to a profit of KRW 3.35 billion in 2024, then to a loss of KRW 7.01 billion in 2025. The company linked the 2025 decline to the absence of large one-off gains such as land sales.
Operating cash flow stayed negative at -KRW 795 million in 2023, -KRW 1.16 billion in 2024, and -KRW 3.07 billion in 2025. The debt ratio rose from 5.7% in 2024 to 55.3% in 2025, with total equity of KRW 50.3 billion and total liabilities of KRW 27.8 billion at year-end 2025.
Quarterly revenue fell from KRW 1.62 billion in the third quarter of 2025 to KRW 1.39 billion and KRW 1.2 billion, then rose to KRW 1.97 billion and KRW 3.02 billion, marking two straight quarters of growth.
Operating losses narrowed each quarter in 2026, from KRW 1.87 billion in the first quarter to KRW 1.15 billion and KRW 572 million. By contrast, the fourth-quarter 2025 net loss attributable to controlling shareholders of KRW 5.04 billion reflected derivative valuation losses. In the first half of 2026, ordinary R&D expenses reached KRW 3.1 billion, up 84% year on year.